Achilles Therapeutics plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the quarter, the company's loss from operations was $13,708,000 compared to $5,566,000 a year ago. Net loss was $13,765,000 compared to $5,214,000 a year ago. Net loss per share attributable to ordinary shareholders-basic and diluted was $8.38 compared to $6.13 a year ago.